Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

NCT07401992 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis (PsO)
Obesity & Overweight
Diabetes Mellitus - Type 2

Interventions

DRUG: Semaglutide (Rybelsus®)
DRUG: Placebo

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez